Company Profile

Coherus BioSciences, Inc. Stock Price, News & Analysis

United StatesBiotechnologyNASDAQ

Company overview

Business overview

Coherus BioSciences is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Geographic Base and Sector Classification

Headquartered in the United States and listed on NASDAQ, Coherus BioSciences is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.

Business Model Characteristics

Coherus BioSciences follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.

Position Within the Biotechnology Landscape

Compared with more mature healthcare names, Coherus BioSciences sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.

Why the stock is moving

CHRS is trading with a steady catalyst profile while investors wait for the next headline that changes the story.

Future catalysts

Coherus BioSciences's catalysts are LOQTORZI launch execution and the biosimilar portfolio, with the market watching whether the business can keep rebuilding after restructuring. The next update matters if it shows the commercial base is finally stabilizing.

Recent news

The five most recent feed items are shown below in reverse chronological order.

  1. 01
  2. 02

    Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference

    Source: Coherus BioSciences, Inc.

  3. 03
  4. 04

    Coherus Oncology, Inc. Announces Proposed Public Offering of Common Stock

    Source: Coherus BioSciences, Inc.

  5. 05

    Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock

    Source: Coherus BioSciences, Inc.

Similar stocks

Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.